# Julian D. Gillmore

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/julian-d-gillmore/

## Facts

| Field | Value |
| --- | --- |
| Citations | 35,749 |
| Field | Amyloidosis: Diagnosis, Treatment, Outcomes |
| h-index | 98 |
| i10-index | 285 |
| Last Known Institution | Alnylam Pharmaceuticals (United States) |
| OpenAlex ID | https://openalex.org/A5057365396 |
| ORCID iD | https://orcid.org/0000-0001-6174-9232 |
| Works | 570 |

## Researcher papers

- [The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group](https://scholariq.org/papers/the-evaluation-of-monoclonal-gammopathy-of-renal-significance-a-consensus-report/)
- [Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy](https://scholariq.org/papers/vutrisiran-in-patients-with-transthyretin-amyloidosis-with-cardiomyopathy/)
- [Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis](https://scholariq.org/papers/patisiran-treatment-in-patients-with-transthyretin-cardiac-amyloidosis/)
- [Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy](https://scholariq.org/papers/eplontersen-for-hereditary-transthyretin-amyloidosis-with-polyneuropathy/)
- [Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study](https://scholariq.org/papers/long-term-safety-and-efficacy-of-patisiran-for-hereditary-transthyretin-mediated/)

## Researcher topics

- [Amyloidosis: Diagnosis, Treatment, Outcomes](https://scholariq.org/topics/amyloidosis-diagnosis-treatment-outcomes/)
- [Parathyroid Disorders and Treatments](https://scholariq.org/topics/parathyroid-disorders-and-treatments/)
- [Alzheimer's disease research and treatments](https://scholariq.org/topics/alzheimer-s-disease-research-and-treatments/)
- [Dermatological and Skeletal Disorders](https://scholariq.org/topics/dermatological-and-skeletal-disorders/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)

## Researcher university

- [Alnylam Pharmaceuticals (United States)](https://scholariq.org/institutions/alnylam-pharmaceuticals-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.